AB Sciex, a Framingham company focused on life sciences analytical technologies, unveiled a global initiative focused on biologics Monday.

This new initiative is in response to the fundamental shift of the pharmaceutical industry into biopharmaceutical development, the company said in a press release.

“We recognize biologics for its strategic importance to the pharmaceutical industry,” Ab Sciex president Rainer Blair said in a statement. “Ab Sciex is well-positioned with our industry-leading hardware platforms and our unique combination of strengths in both large molecule characterization and pharmaceutical analysis. We are working closely with pharmaceutical scientists to develop and shape new software solutions that directly address the needs and requirements for the new frontier of drug discovery and development.”